Minimal Residual Disease in Acute Leukemia 1986: 45 (Developments in Oncology, 45) - Image 1

£179.96

Springer Minimal Residual Disease in Acute Leukemia 1986: 45 (Developments in Oncology, 45)

Name: Minimal Residual Disease in Acute Leukemia 1986: 45 (Developments in Oncology, 45)
Brand: Springer
Price: 179.96 GBP
Availability: InStock

Oncology

Price History & Forecast

Last 3 days • 3 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 3 days • 1 price levels

Days at Price

Price Analysis

Most common price: £180 (3 days, 100.0%)

Price range: £180 - £180

Price levels: 1 different prices over 3 days

Description

Relapse of leukemia following successful remission-induction therapy remains a major obstacle in the treatment of patients with acute leukemia. Leukemia recurs most frequently in patients with acute myeloblastic leukemia (AML) and high risk acute lymphoblastic leukemia (ALL) following chemotherapy and less often in patients with low risk ALL and particularly in patient groups> submitted to allogeneic marrow transplantation. ' It is likely that the great majority of these recurrences originate from residual leukemic cells that survive initial remission-induction chemotherapy. Today, several research groups throughout the world place emphasis on studies concerned with the detection and treatment of 'minimal residual disease' (MRD). These investigations are conducted with the common objective to tackle the remaining cells. 'Minimal Residual Disease in Acute Leukemia: 1986' summarizes the fast advancements in this area. Several disciplines are concerned with the analysis of leukemic cells. The perspectives of cytogenetic and molecular genetic approaches for applica tion in the detection of MRD are reviewed. In this respect, modern cyto genetics provide highly specific tumor markers. The resolution of cyto genetic methods can be particularly improved when combined with other techniques which select relevant subpopulations of cells. Characterization of oncogenes and gene rearrangements, including those of immunoglobulin and T-cell receptor genes, and the measurement of gene products, have been established. Techniques based on these approaches offer interesting tools for the detection of MRD. New possibilities of employing monoclonal anti bodies are also presented.

Product Specifications

Brand: Springer
Format: hardcover
ASIN: 089838799X
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 31 March 1986
Listed Since: 23 January 2007

Barcode

No barcode data available

Springer Minimal Residual Disease in Acute Leukemia 1986: 45 (Developments in Oncology, 45)

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Minimal Residual Disease in Acute Leukemia 1986: 45 (Developments in Oncology, 45)

Chronic and Acute Leukemias in Adults: 26 (Cancer Treatment and Research, 26)

Acute Myeloid Leukemia (Hematologic Malignancies)

Molecular Genetics and Therapy of Leukemia: 84 (Cancer Treatment and Research, 84)

Springer - New Agents for the Treatment of Acute Lymphoblastic Leukemia

Therapie der akuten Leukämien

Acute Leukemias (Hematologic Malignancies)

Advance in the Treatment of Pediatric Leukemia

Chronic and Acute Leukemias in Adults: 26 (Cancer Treatment and Research, 26)

Targeted Therapy of Acute Myeloid Leukemia (Current Cancer Research)

Pathogenesis and Treatment of Leukemia

Preleukemia

Childhood Acute Lymphoblastic Leukemia

Molecular Aspects of Hematologic Malignancies: Diagnostic Tools and Clinical Applications (Principles and Practice)

Chemotherapy for Leukemia: Novel Drugs and Treatment

Leukemias

Hematologic Malignancies: An Overview - Hematology Research

Leukemia Stem Cells in Hematologic Malignancies: 1143 (Advances in Experimental Medicine and Biology, 1143)

CHRONIC MYELOID LEUKEMIA FROM DAILY MA: From Daily Management to Complicated Issues (Cancer Etiology, Diagnosis and Treatments)

Hodgkin’s Disease in Children: Controversies and Current Practice: 41 (Cancer Treatment and Research)

Drug Resistance in Leukemia and Lymphoma III: 457 (Advances in Experimental Medicine and Biology, 457)

Drug Resistance in Leukemia and Lymphoma III: 457 (Advances in Experimental Medicine and Biology, 457)

Myelodysplastic Syndromes: Pathobiology and Clinical Management: 36 (Basic and Clinical Oncology)

Acute Myelogenous Leukemia (Contemporary Hematology)